ALPMF Recent News Astellas Secures Exclusive Righ
Post# of 5
Posted On: 03/02/2014 11:39:48 AM
ALPMF Recent News
Astellas Secures Exclusive Rights to Commercialize Isavuconazole in the U.S. and Canada PR Newswire - Fri Feb 28, 6:00AM CST
Basilea swaps its isavuconazole North American co-promote rights for full isavuconazole rights outside of North America GlobeNewswire - Fri Feb 28, 12:20AM CST
Lupus Nephritis Global Clinical Trials Review, H1, 2014 Research Report M2 - Mon Feb 24, 3:18AM CST
MEDA: Year-End Report January-december 2013 Business Wire - Wed Feb 19, 1:12AM CST
Primco Files Preliminary Form 14c to Increase Authorized Shares PR Newswire - Tue Feb 18, 11:30PM CST
Competitor Analysis: Clostridium Difficile Vaccines and Therapeutics M2 - Tue Feb 18, 2:37AM CST
AVEO Oncology & Astellas Pharma Inc to terminate worldwide collaboration & license agreement for tivozanib and discontinue Phase 2 BATON study for colorectal cancer M2 - Mon Feb 17, 6:21AM CST
Announcement of Intention to Privatize and Invitation to Express Interest PR Newswire - Thu Feb 13, 4:31AM CST
Vical Reports 2013 Financial Results and Progress in Key Development Programs GlobeNewswire - Wed Feb 12, 5:30AM CST
Astellas Secures Exclusive Rights to Commercialize Isavuconazole in the U.S. and Canada PR Newswire - Fri Feb 28, 6:00AM CST
Basilea swaps its isavuconazole North American co-promote rights for full isavuconazole rights outside of North America GlobeNewswire - Fri Feb 28, 12:20AM CST
Lupus Nephritis Global Clinical Trials Review, H1, 2014 Research Report M2 - Mon Feb 24, 3:18AM CST
MEDA: Year-End Report January-december 2013 Business Wire - Wed Feb 19, 1:12AM CST
Primco Files Preliminary Form 14c to Increase Authorized Shares PR Newswire - Tue Feb 18, 11:30PM CST
Competitor Analysis: Clostridium Difficile Vaccines and Therapeutics M2 - Tue Feb 18, 2:37AM CST
AVEO Oncology & Astellas Pharma Inc to terminate worldwide collaboration & license agreement for tivozanib and discontinue Phase 2 BATON study for colorectal cancer M2 - Mon Feb 17, 6:21AM CST
Announcement of Intention to Privatize and Invitation to Express Interest PR Newswire - Thu Feb 13, 4:31AM CST
Vical Reports 2013 Financial Results and Progress in Key Development Programs GlobeNewswire - Wed Feb 12, 5:30AM CST
(0)
(0)Astellas Pharma Inc (ALPMF) Stock Research Links
Scroll down for more posts ▼